Galectin 3- A potential Biomarker for Severe COVID 19

Researchers have measured the galectin-3 levels in the sera of hospitalized patients with coronavirus disease 2019 (COVID-19). They found initial high levels indicate patients will become severely ill, suggesting it could be used as a predictor of severe disease. Here, Galectin 3 is known to drive neutrophilic infiltration and release of pro-inflammatory cytokines leading to airway inflammation. There is a recent update about Galectin 3 being the best prognostic tool for severe cases of COVID 19.

A clinical study published on a preprint server had analyzed 156 hospitalized patients with COVID 19, it was observed that patients diagnosed with covid 19 as critically ill (more than 50 % lung damage) had elevated serum Galectin 3 levels than the patient diagnosed as moderately ill (less than 50 % lung damage). Also, it was observed that patients who progressed to severe outcomes such as mechanical ventilation or in-hospital death have higher levels of Galectin 3.

This makes Galectin 3 a useful tool and prognostic marker especially for severely ill COVID 19 patients. Such a useful tool can work in providing the prognosis and outcome of the COVID 19 diseases. With Galectin 3, medical health professionals can help the patients with a better line of treatment and prognosis. So this gives quite an informative update that circulating Galectin 3 can definitely help in predicting the cases of severe outcomes that need ventilation therapy or are more inclined to death.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.medrxiv.org/content/10.1101/2021.02.07.21251281v1

#Featured